LU83808A1 - Preparation pharmacologique de 1,6-diphosphate de fructose exercant une action therapeutique sur des patients atteints de brulures - Google Patents

Preparation pharmacologique de 1,6-diphosphate de fructose exercant une action therapeutique sur des patients atteints de brulures Download PDF

Info

Publication number: LU83808A1
Authority: LU; Luxembourg
Prior art keywords: diphosphate; burns; patients; fructose; therapeutic action
Prior art date: 1981-01-13

Application number

LU83808A

Other languages

English (en)

French (fr)

Inventor

Renato Costrini

Luciano Cattani

Original Assignee

Foscama Biomedia Chim Farma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-01-13

Filing date

1981-12-03

Publication date

1982-05-07

1981-12-03 Application filed by Foscama Biomedia Chim Farma filed Critical Foscama Biomedia Chim Farma

1982-05-07 Publication of LU83808A1 publication Critical patent/LU83808A1/fr

Links

RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 title claims description 12
229940025237 fructose 1,6-diphosphate Drugs 0.000 title claims description 12
238000002360 preparation method Methods 0.000 title claims description 11
230000000144 pharmacologic effect Effects 0.000 title claims description 9
230000001225 therapeutic effect Effects 0.000 title claims description 7
239000001177 diphosphate Substances 0.000 claims description 18
239000005715 Fructose Substances 0.000 claims description 17
159000000000 sodium salts Chemical class 0.000 claims description 9
229930091371 Fructose Natural products 0.000 claims description 6
230000037396 body weight Effects 0.000 claims description 5
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
239000007864 aqueous solution Substances 0.000 claims description 2
230000000699 topical effect Effects 0.000 claims 1
238000011282 treatment Methods 0.000 description 18
229960002737 fructose Drugs 0.000 description 16
235000011180 diphosphates Nutrition 0.000 description 15
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 14
241000699670 Mus sp. Species 0.000 description 10
238000012360 testing method Methods 0.000 description 9
208000037157 Azotemia Diseases 0.000 description 8
239000008280 blood Substances 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
238000010606 normalization Methods 0.000 description 8
230000002503 metabolic effect Effects 0.000 description 7
230000008929 regeneration Effects 0.000 description 7
238000011069 regeneration method Methods 0.000 description 7
208000035126 Facies Diseases 0.000 description 6
230000000694 effects Effects 0.000 description 5
238000000034 method Methods 0.000 description 5
230000008569 process Effects 0.000 description 5
102000004877 Insulin Human genes 0.000 description 4
108090001061 Insulin Proteins 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
230000004075 alteration Effects 0.000 description 4
230000002641 glycemic effect Effects 0.000 description 4
229940125396 insulin Drugs 0.000 description 4
235000021476 total parenteral nutrition Nutrition 0.000 description 4
239000003792 electrolyte Substances 0.000 description 3
230000006680 metabolic alteration Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
206010001488 Aggression Diseases 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
230000016571 aggressive behavior Effects 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000008103 glucose Substances 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
230000003902 lesion Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000016236 parenteral nutrition Nutrition 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
241000700198 Cavia Species 0.000 description 1
208000032943 Fetal Distress Diseases 0.000 description 1
206010016855 Foetal distress syndrome Diseases 0.000 description 1
206010049645 Hypercatabolism Diseases 0.000 description 1
206010051161 Hyperglucagonaemia Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
235000011613 Pinus brutia Nutrition 0.000 description 1
241000018646 Pinus brutia Species 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241001275831 Tanais Species 0.000 description 1
206010046792 Uterine hypotonus Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000011976 chest X-ray Methods 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000004868 gas analysis Methods 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
230000035880 hyperglucagonemia Effects 0.000 description 1
230000003345 hyperglycaemic effect Effects 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000004130 lipolysis Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
230000000050 nutritive effect Effects 0.000 description 1
238000009519 pharmacological trial Methods 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

LU83808A 1981-01-13 1981-12-03 Preparation pharmacologique de 1,6-diphosphate de fructose exercant une action therapeutique sur des patients atteints de brulures LU83808A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT4755481		1981-01-13
IT47554/81A IT1170618B (it)	1981-01-13	1981-01-13	Preparato farmacologico di frutto sio-1,6-difosfato ad azione terapeutica nei pazienti ustionati

Publications (1)

Publication Number	Publication Date
LU83808A1 true LU83808A1 (fr)	1982-05-07

Family

ID=11261053

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU83808A LU83808A1 (fr)	1981-01-13	1981-12-03	Preparation pharmacologique de 1,6-diphosphate de fructose exercant une action therapeutique sur des patients atteints de brulures

Country Status (9)

Country	Link
JP (1)	JPS57139016A (it)
AU (1)	AU7889081A (it)
BE (1)	BE891316A (it)
DE (1)	DE3150527A1 (it)
FR (1)	FR2497667A1 (it)
GB (1)	GB2092001B (it)
IT (1)	IT1170618B (it)
LU (1)	LU83808A1 (it)
NL (1)	NL8105073A (it)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1156103B (it) *	1982-07-02	1987-01-28	Foscama Biomed Chim Farma	Preparato di fruttosio-1,6-difosfato ad azione antiallergica
IT1164363B (it) *	1983-08-03	1987-04-08	Foscama Biomed Chim Farma	Procedimento terapeutico facente uso di liposomi imcorporati fruttosio 1,6 difosfato e procedimento per la preparazione degli stessi
IT1204764B (it) *	1986-01-17	1989-03-10	Foscama Biomed Chim Farma	Utilizzazione terapeutica del fruttosio-1,6-difosfato per la protezione nei confronti della tossicita' indotta da somministrazione di antitumorali antraciclinici
US4847078A (en) *	1987-01-14	1989-07-11	Arseco, Inc.	Storage stable topical composition having moisture control agent
CA2016709A1 (en) *	1989-05-15	1990-11-15	University Of Cincinnati	Stable aqueous solution having high concentrations of calcium and phosphate ions and solid complex
GB9205800D0 (en) *	1992-03-17	1992-04-29	British Tech Group	Treatment of fibrotic disorders
KR100836033B1 (ko) *	2002-05-27	2008-06-09	(주)아모레퍼시픽	프럭토스 1,6-디포스페이트 또는 그 유도체를 함유한미백용 피부외용제 조성물
ITPD20060082A1 (it) *	2006-03-13	2007-09-14	Laura Martelli	Composizione ad uso cosmetico o dermatologico

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR6065M (it) *	1966-11-25	1968-05-27
US3931402A (en) *	1970-12-02	1976-01-06	Societa Prodotti Antibiotici S.P.A.	Preparations containing hexoses
DE2508474A1 (de) *	1975-02-27	1976-09-02	Boehringer Mannheim Gmbh	Infusions- und spuelfluessigkeiten zur behandlung von hirnoedemen
IT1162443B (it) *	1979-01-16	1987-04-01	Foscama Biomed Chim Farma	Sale ferrico del fruttosio-1,6-difosfato procedimento per la sua produzione e sua utilizzazione nella preparazione dell'acido fruttosio-1,6-difosforico
IT1143956B (it) *	1980-03-12	1986-10-29	Foscama Biomed Chim Farma	Preparato di fruttosio-1,6-difosfato ad azione protettiva della membrana degli eritrociti in pazienti sottoposti a circolazione extracorporea

1981
- 1981-01-13 IT IT47554/81A patent/IT1170618B/it active
- 1981-11-10 NL NL8105073A patent/NL8105073A/nl not_active Application Discontinuation
- 1981-12-01 BE BE0/206709A patent/BE891316A/fr not_active IP Right Cessation
- 1981-12-03 LU LU83808A patent/LU83808A1/fr unknown
- 1981-12-21 DE DE19813150527 patent/DE3150527A1/de not_active Withdrawn
- 1981-12-24 AU AU78890/81A patent/AU7889081A/en not_active Abandoned
- 1981-12-30 FR FR8124524A patent/FR2497667A1/fr active Pending
1982
- 1982-01-07 GB GB8200440A patent/GB2092001B/en not_active Expired
- 1982-01-12 JP JP57003986A patent/JPS57139016A/ja active Granted

Also Published As

Publication number	Publication date
DE3150527A1 (de)	1982-08-12
NL8105073A (nl)	1982-08-02
FR2497667A1 (fr)	1982-07-16
GB2092001B (en)	1985-01-23
BE891316A (fr)	1982-03-31
IT1170618B (it)	1987-06-03
JPH0155249B2 (it)	1989-11-22
IT8147554A0 (it)	1981-01-13
AU7889081A (en)	1982-07-22
GB2092001A (en)	1982-08-11
JPS57139016A (en)	1982-08-27

Publication	Publication Date	Title
Tsai et al.	2008	Neuroprotective effects of recombinant human granulocyte colony-stimulating factor (G-CSF) in neurodegeneration after optic nerve crush in rats
CA1327310C (fr)	1994-03-01	Procede pour augmenter la production laitiere chez les mammiferes et/ou accroitre le poids de leurs nouveaux-nes a la naissance et ameliorer la croissance post-natale
Huang et al.	2018	Arginase-2 protects myocardial ischemiareperfusion injury via NF-κB/TNF-α pathway.
LU83808A1 (fr)	1982-05-07	Preparation pharmacologique de 1,6-diphosphate de fructose exercant une action therapeutique sur des patients atteints de brulures
JP2008533132A (ja)	2008-08-21	ジンセノサイドを含む糖尿病または血糖調節異常の予防または治療用薬学組成物
JP2013503821A (ja)	2013-02-04	血栓症に対処するための医薬組成物、ならびにその調製方法および使用
FR2551659A1 (fr)	1985-03-15	Composition retinoprotectrice a base de chlorhydrate de 2-ethyl-6-methyl-3 hydroxypyridine
JPH10502367A (ja)	1998-03-03	糖尿病を予防するためのｉｇｆ−ｉ又はその類似体の使用
US6809084B1 (en)	2004-10-26	Compositions containing polysaccharides from phellinus linteus and methods for treating diabetes mellitus using same
Nabavizadeh et al.	2009	Direct ex vivo effects of herbal extracts on serum bilirubin in neonatal blood samples
KR100542809B1 (ko)	2006-01-11	혈당 강하용 생약 조성물, 이의 제조방법 및 이를포함하는 약학제재
TW200938216A (en)	2009-09-16	Use of black soybean for treating ophthalmic diseases
CN115531416B (zh)	2025-06-27	星形胶质细胞外泌体及褪黑素预处理在视神经损伤治疗中的应用
RU2143902C1 (ru)	2000-01-10	Способ лечения метаболического синдрома х
CN116747257A (zh)	2023-09-15	治疗或预防心功能不全或心力衰竭的中药组合物
CN1258371C (zh)	2006-06-07	包括大根草有机提取物的组合物及其应用
FR2551975A1 (fr)	1985-03-22	Medicament a action antiarythmique a base de lappaconitine
WO2020029221A1 (zh)	2020-02-13	具有抑制脂肪形成及抗氧化活性的组合物及其用途
WO2017121764A1 (en)	2017-07-20	Pharmaceutical formulations for the treatment of diabetes
Valente et al.	1987	Familial histiocytic dermatoarthritis: Histologic and ultrastructural findings in two cases
FR2485373A1 (fr)	1981-12-31	Substance antivirale et procede pour sa fabrication
CN119097637B (zh)	2025-04-15	核桃膳食纤维在制备治疗帕金森病药物中的应用
de Knegt et al.	1994	Encephalopathy from acute liver failure and from acute hyperammonemia in the rabbit. A clinical and biochemical study
EP0651649A1 (fr)	1995-05-10	Procede d'administration de solutons de facteur de stimulation des colonies granulocytaires
EP1742651A2 (en)	2007-01-17	Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment